Anti-Mouse CD8a Monoclonal Antibodies

Background

The rat anti-mouse CD8a monoclonal antibody 2.43  (rat IgG2b kappa) reacts with the mouse CD8a protein (T-cell surface glycoprotein CD8 alpha chain) encoded by the mouse CD8A gene that encodes the CD8a chain of the dimeric CD8 protein. The mouse CD8 protein is primarily responsible for cell-mediated immune defense and T-cell development. CD8A has been widely reported as a potential prognosis and diagnostic marker for several diseases, such as inflammatory disorders and tumors. It was shown that the anti-mouse CD8a rat monoclonal antibody (clone number: 2.43) can be used for depleting activity in vivo.

Our recombinant 2.43 antibodies have a part (variable regions) or complete amino acid sequences of the rat anti-mouse CD8a monoclonal antibody (hybridoma clone name or number: 2.43).

PA007167.m2a: In Vivo Grade Recombinant Anti-Mouse CD8a Mouse IgG2a Kappa Monoclonal Antibody

The in vivo grade recombinant anti-mouse CD8a mouse IgG2a monoclonal antibody was produced in mammalian cells.
Specificity: CD8a.
Clone: 2.43.
Isotype: mouse IgG2a, kappa.
Applications: Western blot, immunohistochemistry (IHC), Flow Cytometry (FC), and in vivo CD8+ T cell depletion.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

PA007167.r2b: In Vivo Grade Recombinant Anti-Mouse CD8a Rat IgG2b Kappa Monoclonal Antibody

The in vivo grade recombinant anti-mouse CD8a rat IgG2b monoclonal antibody was produced in mammalian cells.
Specificity: CD8a.
Clone: 2.43.
Isotype: rat IgG2b, kappa.
Applications: Western blot, immunohistochemistry (IHC), Flow Cytometry (FC), and in vivo CD8+ T cell depletion.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

Shipping: The in vivo grade recombinant anti-mouse CD8a antibodies (clone of 2.43) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
1 month from date of receipt, 2 to 8°C as supplied.
3 months from date of receipt, -20°C to -70°C as supplied.

References of anti-mouse CD8a antibody (2.43)

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Hsu J, et al. (2018). J Clin Invest. 2018 Oct 1;128(10):4654-4668. doi: 10.1172/JCI99317. PMID: 30157426
To deplete CD8+ T cells, 100 ?g of 2.43 antibody was injected intraperitoneally into mice 3 days prior to tumor implantation and every 3?4 days thereafter. ... NK cells were depleted using anti-NK1.1 (clone PK136) administered on the same schedule as anti-CD8 antibodies. ... Tumor growth was monitored by caliper measurements, and tumor volume was calculated as (length × width?)/2. ... Anti-PD-L1 treatment significantly reduced tumor growth in the presence of NK cells but not in their absence. ... Flow cytometry was used to confirm the depletion of CD8+ T cells and NK cells in treated mice.
Tags: anti-mouse CD8a antibody; 2.43 antibody

CD4 T cells mediate cardiac xenograft rejection via host MHC Class II
Plenter RJ, et al. (2012). J Heart Lung Transplant. 2012 Jul;31(7):781-9. doi: 10.1016/j.healun.2012.03.018. PMID: 22560623
To deplete CD4 T cells, 20 mg/kg of anti-CD4 antibody (clone GK1.5) was injected intraperitoneally into mice, while CD8 depletion was accomplished with 20 mg/kg of 2.43 antibody. ... Cardiac xenografts were transplanted into the abdomen of recipient mice and monitored for rejection. ... Rejection was assessed by palpation, with cessation of graft beating indicating rejection. ... Flow cytometry confirmed the efficacy of T cell depletion in peripheral blood. ... Host MHC Class II expression was critical for CD4 T cell-mediated xenograft rejection.
Tags: anti-mouse CD8a 2.43 antibody; anti-mouse CD8a 2.43 in vivo

Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of ?-L-iduronidase in mice with mucopolysaccharidosis type I
Osborn MJ, et al. (2011). Mol Ther. 2011 Mar;19(3):450-60. doi: 10.1038/mt.2010.249. PMID: 21151097
For CD8 depletion, immunocompetent mice were treated with MC gene transfer and anti-CD8 antibody (2.43). ... Minicircle DNA was administered hydrodynamically to deliver the ?-L-iduronidase gene. ... Immune modulation was achieved by co-administration of CTLA4-Ig to suppress T cell responses. ... Long-term expression of ?-L-iduronidase was confirmed by enzymatic activity assays in liver tissue. ... Treated mice showed reduced glycosaminoglycan accumulation, indicating therapeutic efficacy.
Tags: anti-mouse CD8a 2.43 in animal model; anti-mouse CD8a 2.43 in cancer research

?-Galactosylceramide-loaded, antigen-expressing B cells prime a wide spectrum of antitumor immunity
Kim YJ, et al. (2008). Int J Cancer. 2008 Jun 15;122(12):2774-83. doi: 10.1002/ijc.23444. PMID: 18316581
To deplete CD8+ cells in vivo, 0.5 mg of 2.43 antibody was intraperitoneally injected on days 1 and 3. ... B cells were loaded with ?-galactosylceramide and pulsed with tumor antigens before injection. ... Tumor growth was monitored in B16 melanoma-bearing mice. ... The combination of ?-GalCer and antigen-loaded B cells enhanced antitumor immunity. ... Flow cytometry analysis confirmed the activation of NKT cells in treated mice.
Tags: anti-mouse CD8a 2.43 in mouse tumor model; function of anti-mouse CD8a 2.43

NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation
Xu D, et al. (2004). Int J Cancer. 2004 Feb 20;109(4):499-506. doi: 10.1002/ijc.11696. PMID: 14627990
To identify the cell types responsible for antitumor activity, leukocytes were depleted in vivo every other day for 3 times with 2.43 antibody (rat anti-mouse CD8). ... IL-12 gene therapy was delivered intratumorally to B16-F10 melanoma-bearing mice. ... 4-1BB costimulation was provided via agonistic anti-4-1BB antibody injections. ... Tumor regression was significantly enhanced in the combined treatment group. ... Depletion of NK cells or CD8+ T cells abrogated the therapeutic effect.
Tags: bioactivity of anti-mouse CD8a 2.43; anti-mouse CD8a 2.43 antibody of low endotoxin

Interferon-? enhances resolution of herpes simplex virus type 2 infection of the murine genital tract
Milligan GN, et al. (1997). Virology. 1997 Mar 3;229(1):259-68. doi: 10.1006/viro.1997.8441. PMID: 9180608
CD8+ T cells were neutralized in vivo by intraperitoneal administration of anti-CD8 monoclonal antibody (clone 2.43). ... Mice were infected intravaginally with herpes simplex virus type 2 (HSV-2). ... IFN-? levels were measured in vaginal secretions to assess immune response. ... Flow cytometry confirmed the depletion of CD8+ T cells in treated mice. ... IFN-? treatment enhanced viral clearance in the absence of CD8+ T cells.
Tags: anti-mouse CD8a (2.43) in vivo antibody; clone 2.43 of anti-mouse CD8a antibody

For more references about anti-mouse CD8a antibody (2.43), please contact our scientific support team with message@sydlabs.com.

In Vivo Grade Recombinant Anti-Mouse CD8a Monoclonal Antibodies (Clone 2.43):
In Vivo Grade Recombinant Anti-Mouse CD8a Mouse IgG2a Monoclonal Antibody
In Vivo Grade Recombinant Anti-Mouse CD8a Mouse Fab Fragment
In Vivo Grade Recombinant Anti-Mouse CD8a Rat IgG2b Monoclonal Antibody

Syd Labs provides the following recombinant anti-human CD8a monoclonal antibodies:
In vivo grade recombinant anti-human CD8a antibodies (clone OKT8)
Recombinant anti-human CD8a antibodies (clone OKT8) for flow cytometry

Syd Labs provides the following recombinant anti-mouse CD8a monoclonal antibodies:
In vivo grade recombinant anti-mouse CD8a antibodies (clone 2.43)
In vivo grade recombinant anti-mouse CD8a antibodies (clone YTS 169.4)
In vivo grade recombinant anti-mouse CD8a antibodies (clone YTS 105.18)

Syd Labs provides the following recombinant anti-mouse CD8b monoclonal antibodies:
In vivo grade recombinant anti-mouse CD8b antibodies (clone YTS 156.7)